Companies / Prime Medicine, Inc.

Prime Medicine, Inc.

Nasdaq: PRMECIK 1894562CAMBRIDGE, MA

Financials · FY2025

Revenue$4.63M
Net income$-201.14M
Total debt
Cash$47.45M
Diluted EPS$-1.35
Shares outstanding181.4M

Ownership

181.4M shares outstanding · as of Jul 31, 2026
3.3%10%+ / strategic
Ownership
10%+ / strategic3.31%5,995,183
Institutions52.95%96,045,358
Public float43.74%79,336,315

% of common shares outstanding (exact, from the latest cover-page filing). Institutions are quarterly 13F snapshots; insiders reflect current officers & directors.

Insiders 5

View all →
Insider% of sharesShares
Alenson CarmanFormerSee Remarks
Lee Ann L.Chief Technical Officer
Nelsen RobertDirector · 10% owner
Reine AllanCEOChief Executive Officer · Director

Institutional holders 189

View all →

Activity

InsidersInstitutions
What insiders are doing in this stock (Form 4).
DateActorActionSecurityValueShares ΔPosition afterImpact
Jun 5, 2026Foster-Cheek Kaye I
Director
GrantStock Option (right to buy)+75K
75,000
0.04% of shares
low
Jun 5, 2026Nelsen Robert
Director
GrantStock Option (right to buy)+75K
75,000
0.04% of shares
low
Feb 23, 2026Lee Ann L.
Executive
GrantStock Option (right to buy)+375K
375,000
0.21% of shares
low
Feb 26, 2026Reine Allan
CEO
GrantStock Option (right to buy)+1.3M
1,300,000
0.72% of shares
low
Feb 23, 2026Alenson Carman
Executive
GrantStock Option (right to buy)+140K
140,000
0.08% of shares
low

5%+ ownership events

Schedule 13D / 13G
FilerStance% of classSharesDate
T. Rowe Price Investment Management, Inc.Passive13G/A5,995,183

Securities

via CUSIP / OpenFIGI
SymbolTypeMarketCUSIPFIGI
PRMECommon StockEquity74168J101BBG011RT3R55